Sökning: L773:1435 4373 OR L773:0934 9723 > Early quantificatio...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04183naa a2200481 4500 | |
001 | oai:gup.ub.gu.se/159281 | |
003 | SwePub | |
008 | 240910s2012 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/1592812 URI |
024 | 7 | a https://doi.org/10.1007/s10096-011-1486-52 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Alsiö, Åsa,d 1965u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xalsas |
245 | 1 0 | a Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection |
264 | c 2011-11-24 | |
264 | 1 | b Springer Science and Business Media LLC,c 2012 |
520 | a The aim of the present study was to evaluate the utility of hepatitis C virus (HCV) core antigen (coreAg) assessment for the identification of candidates for short-term therapy. Plasma samples from HCV genotype 2 or 3-infected patients participating in the NORDynamIC trial (n = 382) comparing 12 and 24 weeks of combination treatment with pegylated interferon-alpha 2a and a fixed dose of 800 mg ribavirin daily were analyzed for coreAg. Among the 126 patients (33% of the intention-to-treat population) achieving HCV coreAg levels in plasma below 0.2 pg/mL when assayed on treatment day 3, sustained viral response (SVR) rates of 86% and 84% were achieved in the 12- and 24-week arms, respectively. Similarly, among patients having received at least 80% of the target dose of both pegylated interferon alpha-2a and of ribavirin for at least 80% of the target treatment duration (per-protocol analysis), the SVR rates were 89% and 95%, respectively. Twelve weeks of combination treatment may be sufficient for genotype 2 or 3-infected patients achieving HCV coreAg levels below 0.2 pg/mL by day 3, signaling a rapid clearance of HCV viremia. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
653 | a rapid virological response | |
653 | a chronic hepatitis-c | |
653 | a real-time pcr | |
653 | a peginterferon alpha-2a | |
653 | a plus ribavirin | |
653 | a clinical utility | |
653 | a assay | |
700 | 1 | a Jannesson, A.u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut |
700 | 1 | a Langeland, N.4 aut |
700 | 1 | a Pedersen, C.4 aut |
700 | 1 | a Farkkila, M.4 aut |
700 | 1 | a Buhl, M. R.4 aut |
700 | 1 | a Morch, K.4 aut |
700 | 1 | a Westin, Johan,d 1965u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xwestj |
700 | 1 | a Hellstrand, Kristoffer,d 1956u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xhellk |
700 | 1 | a Norkrans, Gunnar,d 1944u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xnorgu |
700 | 1 | a Lagging, Martin,d 1965u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xlagma |
710 | 2 | a Göteborgs universitetb Institutionen för biomedicin, avdelningen för infektionssjukdomar4 org |
773 | 0 | t European Journal of Clinical Microbiology & Infectious Diseasesd : Springer Science and Business Media LLCg 31:7, s. 1631-1635q 31:7<1631-1635x 0934-9723x 1435-4373 |
856 | 4 8 | u https://gup.ub.gu.se/publication/159281 |
856 | 4 8 | u https://doi.org/10.1007/s10096-011-1486-5 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy